These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 32045673)

  • 1. Bioequivalence studies of inhaled indacaterol maleate in healthy Chinese volunteers under gastrointestinal non-blocking or blocking with concomitant charcoal administration.
    Zou C; Yang Q; Yang S; Zhang X; Yang X; Huang Z; Pei Q; Huang J; Yang G
    Pulm Pharmacol Ther; 2020 Apr; 61():101902. PubMed ID: 32045673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of indacaterol and mometasone furoate delivered alone or in a free or fixed dose combination in healthy subjects.
    Vaidya SS; Khindri S; Calder N; Machineni S; Hara H; Majumdar T; Febbraro S; Fuhr R; Woessner R
    Pulm Pharmacol Ther; 2016 Apr; 37():30-6. PubMed ID: 26845343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lung Delivery of Indacaterol and Mometasone Furoate Following Inhalation of QMF149 in Healthy Volunteers.
    Vaidya SS; Khindri S; Maahs S; Machineni S; Hara H; Juan A; Kaiser G
    Clin Pharmacol Drug Dev; 2016 Jul; 5(4):285-95. PubMed ID: 27310329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and safety of indacaterol and glycopyrronium (IND/GLY) following repeated once daily inhalation from a fixed-dose combination in healthy Chinese subjects
.
    Ren S; Sechaud R; Su Z; Tillmann HC; Hara H; Tan X; Hou J; Woessner R; Zhao R
    Int J Clin Pharmacol Ther; 2017 Feb; 55(2):147-155. PubMed ID: 27841152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of QMF149 in Japanese versus Caucasian subjects: an open-label, randomized phase I study.
    Shimada S; Vaidya S; Khindri S; Tashiro N; Cheng Y; Hara H; Majumdar T; Woessner R; Furihata K; Kobayashi K
    Int J Clin Pharmacol Ther; 2015 May; 53(5):398-407. PubMed ID: 25740265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single- and multiple-dose pharmacokinetics of inhaled indacaterol in healthy Chinese volunteers.
    Jiang J; Li L; Yin H; Woessner R; Emotte C; Li R; Khindri S; Pei H
    Eur J Drug Metab Pharmacokinet; 2015 Jun; 40(2):203-8. PubMed ID: 24705947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Particle size and gastrointestinal absorption influence tiotropium pharmacokinetics: a pilot bioequivalence study of PUR0200 and Spiriva HandiHaler.
    Perry J; Trautman B; Takher-Smith J; Kramer S; Kane K; Silverman M; Tan L; Haughie S; Richter W; Kirkov V; Arsova S; Ward J; Hava DL
    Br J Clin Pharmacol; 2019 Mar; 85(3):580-589. PubMed ID: 30521129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lung function, pharmacokinetics, and tolerability of inhaled indacaterol maleate and acetate in asthma patients.
    Miller D; Vaidya S; Jauernig J; Ethell B; Wagner K; Radhakrishnan R; Tillmann HC
    Respir Res; 2020 Sep; 21(1):248. PubMed ID: 32967685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy, safety and pharmacokinetics of indacaterol in Caucasian and Japanese patients with chronic obstructive pulmonary disease: a comparison of data from two randomized, placebo-controlled studies.
    Hosoe M; Woessner R; Matsushima S; Lawrence D; Kramer B
    Clin Drug Investig; 2011; 31(4):247-55. PubMed ID: 21184620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, tolerability and pharmacokinetics of single escalating doses of indacaterol, a once-daily beta2-agonist bronchodilator, in subjects with COPD.
    Pascoe S; Reynolds C; Pleskow W; Perry S; Hmissi A; Kaiser G; Brookman L
    Int J Clin Pharmacol Ther; 2011 Feb; 49(2):153-61. PubMed ID: 21255532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of an additional dose of indacaterol in COPD patients under regular treatment with indacaterol.
    Cazzola M; Segreti A; Stirpe E; Puxeddu E; Ora J; Rogliani P; Matera MG
    Respir Med; 2013 Jan; 107(1):107-11. PubMed ID: 23083839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of indacaterol, glycopyrronium and mometasone furoate administered as an inhaled fixed-dose combination in Japanese and Caucasian healthy subjects.
    Inoue S; Vaidya S; Tillmann HC; Sakita Y; Machineni S; Heudi O; Furihata K
    BMC Pulm Med; 2021 Jan; 21(1):18. PubMed ID: 33413291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trial.
    Hohlfeld JM; Vogel-Claussen J; Biller H; Berliner D; Berschneider K; Tillmann HC; Hiltl S; Bauersachs J; Welte T
    Lancet Respir Med; 2018 May; 6(5):368-378. PubMed ID: 29477448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative efficacy of indacaterol in chronic obstructive pulmonary disease.
    Ribeiro M; Chapman KR
    Int J Chron Obstruct Pulmon Dis; 2012; 7():145-52. PubMed ID: 22419862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New developments in the management of COPD: clinical utility of indacaterol 75 μg.
    Steiropoulos P; Archontogeorgis K; Nena E; Bouros D
    Int J Chron Obstruct Pulmon Dis; 2014; 9():1-7. PubMed ID: 24353414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sustained 24-hour efficacy of once daily indacaterol (300 μg) in patients with chronic obstructive pulmonary disease: a randomized, crossover study.
    Laforce C; Aumann J; de Teresa Parreño L; Iqbal A; Young D; Owen R; Higgins M; Kramer B;
    Pulm Pharmacol Ther; 2011 Feb; 24(1):162-8. PubMed ID: 20619353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of indacaterol in the treatment of patients with COPD.
    Donohue JF; Singh D; Kornmann O; Lawrence D; Lassen C; Kramer B
    Int J Chron Obstruct Pulmon Dis; 2011; 6():477-92. PubMed ID: 22003293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bronchodilator efficacy and safety of indacaterol 150 μg once daily in patients with COPD: an analysis of pooled data.
    Bleecker ER; Siler T; Owen R; Kramer B
    Int J Chron Obstruct Pulmon Dis; 2011; 6():431-8. PubMed ID: 22003288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies.
    Kerwin EM; Gotfried MH; Lawrence D; Lassen C; Kramer B
    Clin Ther; 2011 Dec; 33(12):1974-84. PubMed ID: 22177371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison.
    Rennard S; Bantje T; Centanni S; Chanez P; Chuchalin A; D'Urzo A; Kornmann O; Perry S; Jack D; Owen R; Higgins M
    Respir Med; 2008 Jul; 102(7):1033-44. PubMed ID: 18479895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.